Molecular Diagnostics Market Size, Share, Growth Analysis, By Product & Service(Reagents & Kits, Instruments, Services & Software), Technology(PCR, INAAT, NGS, ISH, DNA Microarrays, Others), Application, Test Type, Sample Type, End User, and Region - Industry Forecast 2024-2031

In May 2024, Bruker Corporation completed the acquisition of ELITechGroup for €870 million in cash excluding ELITech clinical chemistry business. A molecular diagnostics MDx, biomedical systems/specialty IVDs, Microbiology solutions and services provider ELITech posted near about EUR 150 million of FY 2023 revenues and over 80% by Consumable. The acquisition by Bruker is impressive since it brings changes and expansion to the company and situates it as an innovative infectious disease company in the IVD industry. Bruker’s MALDI Biotyper extended its portfolio in molecular diagnostics through the partnership with ELITech, which provides MDx platforms and niche MDx assays targeting niche markets.  

In February 2024, Eurofins Scientific completed the purchase deal of Diatherix Laboratories, Inc. for about US$50 million with an earn out provision for specific kinds of revenue and profitability at the end of the purchase amount. This deal is expected to be closed in 30 days (about 4 and a half weeks) and will post Eurofins’ decisive step on the way to strengthening its positions in the sphere of specialty clinical diagnostics. Based in Huntsville, Alabama, Diatherix focuses has a specialized molecular diagnostics company employing the TEM-PCR™ testing of infectious diseases, providing accurate information quickly. 

In April 2024, Bosch Healthcare and Randox disclosed, they will be working jointly to develop the Vivalytic analysis platform with $159 million (€150 million). With this partnership, the parties intend to create brand-new tests for the Bosch point of care molecular diagnostic device that has a record-fast PCR test turnaround. Attention will be paid to the development of a fast sepsis diagnostics approach. As part of a strategic collaboration, both companies will work together to expand joint research and development and sales and marketing projects. Point of care molecular diagnostics is a promising market where Bosch is targeting to position as a market leader. The chairman of Bosch, Stefan Hartung said, “With technologies developed in house and finest production line in our company we aim at establishing long term cooperation with partners in diagnostics sector".